Kymera Therapeutics Q3 net loss widens to $132.0 million; KT-579 Phase 1 data reported
Kymera Therapeutics reported third quarter 2026 results with a net loss of $132.0 million, up from $82.2 million a year earlier, as collaboration revenue fell to zero from $2.8 million. Research and development expenses rose to $128.5 million from $74.1 million, which the company attributed mainly to its STAT6 program. The company also reported Phase 1 healthy volunteer data for its KT-579 degrader and said it had $1.6 billion in cash, with runway into 2029.
Key points
- Net loss was $132.0 million, or $1.32 per share, versus $82.2 million, or $0.94 per share, in the third quarter of 2025.
- Collaboration revenue was zero versus $2.8 million, and the company does not expect additional collaboration revenue in 2026.
- Research and development expenses were $128.5 million versus $74.1 million.
- Cash, cash equivalents and investments were $1.6 billion as of September 30, 2026; KT-621 BROADEN2 Phase 2b topline data is planned by year-end 2026.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.